

Drug and Therapeutics Committee – Minutes –Approved	
--	--

Date / Time	Thursday 14 th July 2016
Venue	The Board Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Wendy Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes

Attendance	Mr S Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services Mr P O'Brien, Deputy Chief Pharmacist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mrs E Lyle, Locality Pharmacist, Medicines Management, Hull NECS Dr F Umerah, Consultant Anaesthetist Mr R Kapur, Vascular Surgeon Dr O Ogunbambi, Consultant Rheumatologist Prof M Lind, Vice Chair, Professor of Oncology
-------------------	---

Apologies	Dr H Klonin, Consultant Paediatrician
------------------	---------------------------------------

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2016.07.01	Apologies	As above.					
2016.07.02	Declarations of Interest	None.	Noted	No further action			07/16
2016.07.03	Minutes of the previous meeting	The minutes were accepted as a true record.					07/16
2016.07.04	Action Tracker	<p>Action Tracker DC has discussed with Sarah Bates and will follow up to arrange a meeting with the suggested lay member.</p> <p>New Product Requests - Tedizolid KMcC and POB to discuss commissioning further outside meeting</p> <p>MHRA DSU OO has discussed use of live vaccines in immunocompromised patients with Rheumatology colleagues.</p> <p>Correspondence Received SG has informed Dr Barlow of D&T committee's decision re Elderly Medicine Antibiotic Guideline, in agreement with ACAT.</p> <p>Correspondence Received ML has written to Dr Zaman re ivermectin treatment pathway.</p> <p>New Product Requests AM has written to applicants and WH has updated formulary.</p> <p>New Product Requests</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>		<p>DC</p> <p>KMcC/ POB</p>	<p>7/16</p> <p>9/16</p> <p>7/16</p> <p>7/16</p> <p>7/16</p>	<p>7/16</p> <p>7/16</p> <p>7/16</p> <p>7/16</p>

		<p>TA358 POB has confirmed there will be 10 patients over Hull (6) and ER (4) who will be receiving tolvaptan treatment with KMcC.</p> <p>MHRA DSU SG has emailed James Bailey re risk of Hepatitis B.</p> <p>Updated Terms of Reference WH has updated the formulary intranet page with the updated D&TC terms of reference.</p> <p>Correspondence Received SG has still to write to Dr Mohammed regarding the dispersible alendronic acid preparation.</p>	Action complete				7/16
			Action complete				7/16
			Action complete				7/16
			Ongoing		SG	7/16	
2016.07.05	New Product Requests	<ul style="list-style-type: none"> • Obinutuzumab – Dr D Allsup - Approved for use in line with NICE TA343 • Evolocumab – Dr D Narayanan – Approved for use in line with NICE TA394. • Alirocumab – Dr D Narayanan – Approved for use in line with NICE TA393. <p>With regards to the above two PCSK9 inhibitors, POB informed the committee that it had been agreed they would be used in a prescribing pharmacist led clinic which would ensure all patients receiving treatment fitted the NICE criteria. It was agreed that HEY would need a clear statement from both CCGs stating how these two products would be commissioned and recharged in line with NICE. Both drugs are available at discount via PAS schemes.</p> <ul style="list-style-type: none"> • Dulaglutide – Dr K Mohammed – There are currently three GLP-1 receptor agonists on formulary already. Dulaglutide has been approved for use in Wales and Scotland but only as an add on therapy. It was agreed that dulaglutide would have a place in treatment as it has a good delivery device and a wider licensed indication, but further clarification should be sought in which circumstances it would be recommended. 	Approved	AM to write to applicants and WH to update formulary	AM/WH	8/16	
			Approved	Post D&T meeting to be arranged with clinic pharmacist and CCGs to discuss NICE implementation further	POB	8/16	
			Approved	AM to write to Dr Mohammed and request updated guideline	AM	8/16	
			Approved subject to type 2 diabetes guideline being updated to clarify place in therapy				

		The type 2 diabetes guideline would need updating to clarify.					
2016.07.07	NICE Guidance	<ul style="list-style-type: none"> TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa POB informed the committee that this was an NHS England commissioned service working from Leeds/Sheffield. Therefore it was thought there would not be a need for HEY to provide for patients with this indication. Although it was unsure how this would work, as many dermatology patients receive their treatment via homecare. <u>Post-meeting Note:</u> POB has confirmed that NHSE have now identified HEY as a centre for this condition and we will be commissioned to use Adalimumab in HS. A D&T new product request would be sought from the service. TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus 	POB will contact Greg Haire to discuss the situation. Formulary to be annotated accordingly	POB to contact Greg Haire WH to amend formulary as awaiting submission	POB WH	8/16 8/16	
			Approved as above	No further action			7/16
			Approved as above	No further action			7/16
			Not formulary, ML will request application	ML to seek request	ML	8/16	
			Noted, on formulary	No further action			7/16
			Not formulary, OO will request application	OO to seek request	OO	8/16	
2016.07.07	MHRA Drug Safety update	<p>June 16 Cangagliflozin – risk of lower extremity amputation in high CV risk patients - AM will write to endocrinology and highlight alert.</p> <p>Nexplanon- reports of device in vasculature and lung</p>	Notify endocrinology	AM to write to Dr Mohammed	AM	8/16	
			Noted. Used at HEY, but formulary states	WH to update formulary with correct brand	WH	8/16	

		Topical Miconazole – interaction with warfarin	previous Implanon brand					
			Noted	No further action				7/16
2016.07.08	Minutes from Safe Medication Practice Committee	<p>May 16</p> <ul style="list-style-type: none"> DC gave a summary of the meeting. HEY had carried out a 1 day audit of missed doses and had found over 400 doses had been missed in one day, which had led to a range of actions being implemented including the trialling of pharmacy assisted drug rounds. GMC numbers still not written on drugs cards therefore a zero tolerance trial is to take place on ward C33. Incorrect dosing of paracetamol for patients under 50kg had been highlighted in a pre-registration Pharmacist audit. Pharmacy are putting together a package to help address this problem. It was mentioned that when audited only 60% of drug cards included a patient weight and it was felt that this would not help when assessing which dose was most suitable for patients. 	Noted	No further action				7/16
2016.07.09	Correspondence Received	<ul style="list-style-type: none"> SG had received new product request from Lorraine Cullen for artesunate, a new malaria treatment. The committee agreed that as this was an essential medicine it would be acceptable for pharmacy to order a supply in before the review takes place next month. ML had submitted an IFR to NHSE to use everolimus (Votubia) to treat a patient with tuberous sclerosis, which had been turned down. ML informed the committee that there was good evidence that everolimus was effective in the treatment of this condition. POB informed the committee that NHSE had agreed to commission but that ML must be specific in how it would be used. The Clinical Commissioning Policy Statement: Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis was published June/2016: https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/b14x09-ps-everolimus- 	<p>POB to arrange for supply to be kept in pharmacy.</p> <p>ML to provide POB with summary of patient to send to NHSE</p>	<p>POB to arrange supply</p> <p>ML to send to POB, for forwarding to NHSE</p>	<p>POB</p> <p>ML/POB</p>	<p>8/16</p> <p>8/16</p>		

		aml.pdf					
2016.07.10	Chairs Approvals	<ul style="list-style-type: none"> Isavuconazole - chronic aspergillus invasion in cystic fibrosis- Prof A Morice (approved by Dr O Ogunbambi) Apremilast - Psoriatic arthritis, not controlled by methotrexate – Dr Patel 	Noted.	No further action			07/16
2016.07.11	Issues to escalate to OQC	None this month.					07/16
2016.07.12	Any other Business	AM asked if he could add a line extension to the Symbicort range of products, as a new MDI device was available. The committee agreed to this line extension.	Noted	WH to amend formulary	WH	7/16	
	Date and Time of Next Meeting	Thursday 11 th August 2016, 8.15am – 9.30am. The Board Room, Alderson House, HRI					